Outcomes of definitive carbon-ion radiotherapy for cT1bN0M0 esophageal squamous cell carcinoma

被引:0
作者
Isozaki, Tetsuro [1 ,5 ]
Ishikawa, Hitoshi [1 ]
Yamada, Shigeru [1 ]
Nabeya, Yoshihiro [2 ]
Minashi, Keiko [3 ]
Murakami, Kentaro [4 ]
Matsubara, Hisahiro [4 ]
机构
[1] Natl Inst Quantum Sci & Technol, QST Hosp, Chiba, Japan
[2] Chiba Canc Ctr, Div Esophago Gastrointestinal Surg, Chiba, Japan
[3] Chiba Canc Ctr, Clin Trial Promot Dept, Chiba, Japan
[4] Chiba Univ, Grad Sch Med, Dept Frontier Surg, Chiba, Japan
[5] QST Hosp, Dept Radiol, 4-9-1 Anagawa,Inage Ku, Chiba 2638555, Japan
关键词
Carbon-ion radiotherapy; Esophageal carcinoma; Radiotherapy; Particle therapy; CHEMORADIOTHERAPY; THERAPY; LYMPHOPENIA; CANCER; PROTON; TRIAL; BEAM;
D O I
10.1007/s10388-024-01067-7
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BackgroundA recent phase I/II study determined the optimal dose of definitive carbon-ion radiotherapy (CIRT) for cT1bN0M0 esophageal cancer. This study aimed to further confirm the efficacy and feasibility of the recommended dose fractionation of CIRT with long-term follow-up results in a larger sample size.MethodsThis single center retrospective study evaluated patients with cT1bN0M0 esophageal squamous cell carcinoma treated with the recommended dose fractionation of 50.4 Gy relative biological effectiveness in 12 fractions, between 2012 and 2022.ResultsThirty-eight patients underwent CIRT at our hospital. Although eight (21.1%) patients were older than 80 years, 15 (39.5%) had high surgical risk, and seven (18.4%) were at high risk for chemotherapy, all patients underwent CIRT as scheduled. Grade 3 esophagitis occurred in eight (21.1%) patients and grade 3 pneumonia in one (2.6%) patient in this study, but no grade 4 adverse events occurred. The only grade 3 late adverse event was pneumonia in one patient (2.6%). The 5-year overall survival rate, local control rate, and disease-free survival rates were 76.6% (95% CI, 90.9-62.4), 74.9% (95% CI, 90.7-59.0), and 66.4% (95% CI, 83.3-49.5), respectively. Additionally, post CIRT recurrence was as follows: seven (18.4%) patients had recurrence in another part of the esophagus, three (7.9%) in the primary site, three (7.9%) in lymph nodes outside the irradiated area, and one (2.6%) patient had liver metastasis.ConclusionsOur study demonstrates that CIRT using the recommended dose fractionation is feasible and effective for cT1bN0M0 esophageal squamous cell carcinoma.
引用
收藏
页码:523 / 529
页数:7
相关论文
共 27 条
  • [1] Biological gain of carbon-ion radiotherapy for the early response of tumor growth delay and against early response of skin reaction in mice
    Ando, K
    Koike, S
    Uzawa, A
    Takai, N
    Fukawa, T
    Furusawa, Y
    Aoki, M
    Miyato, Y
    [J]. JOURNAL OF RADIATION RESEARCH, 2005, 46 (01) : 51 - 57
  • [2] ctep.cancer, Common terminology criteria for adverse events (CTCAE)
  • [3] Radiotherapy combination opportunities leveraging immunity for the next oncology practice
    Herrera, Fernanda G.
    Bourhis, Jean
    Coukos, George
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2017, 67 (01) : 65 - 85
  • [4] A Phase I/II Trial of Definitive Carbon Ion Radiotherapy for Clinical T1bN0M0 Esophageal Squamous Cell Carcinoma
    Isozaki, Tetsuro
    Ishikawa, Hitoshi
    Yasuda, Shigeo
    Isozaki, Yuka
    Yamada, Shigeru
    Akutsu, Yasunori
    Nagata, Matsuo
    Nabeya, Yoshihiro
    Minashi, Keiko
    Murakami, Kentaro
    Kuwano, Hiroyuki
    Nemoto, Kenji
    Tsuji, Hiroshi
    Uno, Takashi
    Matsubara, Hisahiro
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : 416 - 421
  • [5] The Promise of Combining Radiation Therapy With Immunotherapy
    Jagodinsky, Justin C.
    Harari, Paul M.
    Morris, Zachary S.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (01): : 6 - 16
  • [6] Japanese Classification of Esophageal Cancer, 11th Edition: part I
    Japan Esophageal Society
    [J]. ESOPHAGUS, 2017, 14 (01) : 1 - 36
  • [7] Examination of GyE system for HIMAC carbon therapy
    Kanai, T
    Matsufuji, N
    Miyamoto, T
    Mizoe, J
    Kamada, T
    Tsuji, H
    Kato, H
    Baba, M
    Tsujii, H
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 64 (02): : 650 - 656
  • [8] Irradiation of mixed beam and design of spread-out Bragg peak for heavy-ion radiotherapy
    Kanai, T
    Furusawa, Y
    Fukutsu, K
    Itsukaichi, H
    EguchiKasai, K
    Ohara, H
    [J]. RADIATION RESEARCH, 1997, 147 (01) : 78 - 85
  • [9] Parallel-Group Controlled Trial of Surgery Versus Chemoradiotherapy in Patients With Stage I Esophageal Squamous Cell Carcinoma
    Kato, Ken
    Ito, Yoshinori
    Nozaki, Isao
    Daiko, Hiroyuki
    Kojima, Takashi
    Yano, Masahiko
    Ueno, Masaki
    Nakagawa, Satoru
    Takagi, Masakazu
    Tsunoda, Shigeru
    Abe, Tetsuya
    Nakamura, Tetsu
    Okada, Morihito
    Toh, Yasushi
    Shibuya, Yuichi
    Yamamoto, Seiichiro
    Katayama, Hiroshi
    Nakamura, Kenichi
    Kitagawa, Yuko
    [J]. GASTROENTEROLOGY, 2021, 161 (06) : 1878 - +
  • [10] Proton beam therapy reduces the risk of severe radiation-induced lymphopenia during chemoradiotherapy for locally advanced non-small cell lung cancer: A comparative analysis of proton versus photon therapy
    Kim, Nalee
    Noh, Jae Myoung
    Lee, Woojin
    Park, Byoungsuk
    Park, Heejoo
    Park, Ji Young
    Pyo, Hongryull
    [J]. RADIOTHERAPY AND ONCOLOGY, 2021, 156 : 166 - 173